What are the major factors driving the growth of the human microbiome market?

In the year 2025, the industry size of human microbiome is estimated at USD 561.5 million. Read More

Human Microbiome Market Trends

Growth Drivers

Growing Incidence of Respiratory Diseases – Ongoing studies state that the lung microbiome increases the proneness to respiratory diseases and influences responses to treatment. Hence, the surge in investment in comprehending the lung microbiome to develop both diagnostic and prognostic biomarkers for respiratory diseases in clinical settings will drive market growth.
Increasing Prevalence of Gastrointestinal Disorders – According to a study, globally around 35% of people lived with functional gastrointestinal disorders in 2021. It is expected that with the growing cases of gastrointestinal disorders and digestive health, including diarrhea, constipation, and bowel incontinence, the rising influence of the human gut microbiome in both health and disease is slated to expand the market in the upcoming years.
Rising Health Spending and Extensive Research About Human Microbiome – The increasing involvement of the human microbiome in human metabolism, nutrition, physiology, and immune function is responsible for several ongoing studies on the human microbiome and its function. The rising need to eliminate the growing healthcare expenditure worldwide by improving the gut microbiota and the human microbiome is poised to drive market expansion.

Challenges

Strict Government Rules & Regulations- The emerging regulations by the government for the market are one of the major factors counted to slow down the market growth. For instance, probiotics are regarded as dietary supplements and no microbiome-based probiotics have received FDA approval as live biotherapeutic products (LBP).
Lack of Knowledge about Human Microbiome Products
Absence of Sufficient Research on the Human Microbiome

Human Microbiome Market: Key Insights

Regionally, the global human microbiome market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America is projected to garner the largest revenue of USD 1859.8 Million by the end of 2031, up from a revenue of USD 251.6 Million in the year 2021. The growth of the market in the region can primarily be attributed to the growing expenditure on research and developments (R&D) in the region, presence of a strong healthcare network, along with the surge in initiatives of the governments of the region for promoting research on human health. Besides this, the surge in health expenditure is also expected to add to the market growth in the region during the forecast period. According to the statistics by the World Bank, the current health expenditure as a share of GDP in North America grew from 12.197% in the year 2000 to 16.322% in the year 2019. On the other hand, the market in Europe is projected to register the second-largest revenue of USD 702.3 Million by the end of 2031, up from a revenue of USD 92.9 Million in the year 2021. The market in the region is further segmented by country into Germany, United Kingdom, France, Italy, Spain, Russia, and the Rest of Europe. The market in Germany is projected to garner the largest revenue of USD 169.3 Million by the end of 2031, up from a revenue of USD 21.6 Million in the year 2021.

The study further incorporates Y-O-Y Growth, market opportunities, demand & supply and forecast future opportunity in North America (United States, Canada, Mexico), South America, Europe (U.K., Germany, France, Italy, Spain, Hungary, BENELUX [Belgium, Netherlands, Luxembourg], NORDIC [Norway, Denmark, Sweden, Finland], Poland, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Malaysia, Indonesia, Taiwan, Hong Kong, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).

Base Year	2024
Forecast Year	2025-2037
CAGR	32.2%
Base Year Market Size (2024)	USD 445.92 million
Forecast Year Market Size (2037)	USD 11.73 billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Why is the human microbiome sector gaining traction in near future?

The human microbiome market size was over USD 445.92 million in 2024 and is projected to cross USD 11.73 billion by the end of 2037, witnessing more than 32.2% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of the human microbiome in health and disease and increasing research on its major impact on human physiology, metabolic and immune functions will boost the market growth.

Who are the major human microbiome players?

The major players in the market include Seres Therapeutics, Inc., Evelo Biosciences, Inc., Synlogic, Inc., Second Genome Inc., Synthetic Biologics, Inc., YSOPIA Bioscience, 4D Pharma plc, DuPont de Nemours, Inc., BiomX Inc., Sun Genomics, Inc., Viome Life Sciences, Inc.

Human Microbiome Market Trends